WCO Sri Lanka/ Sri Jayawardanapura University
© Credits

WHO and Sri Lanka jointly review the proposal for a seroprevalence study to measure SARS-CoV-2 antibodies aligned with WHO’S unity sero-epidemiological investigations protocol

22 April 2022
Departmental update
Reading time:

The Epidemiology unit of the Ministry of Health of Sri Lanka has planned to  conduct  a survey to determine  the level of COVID-19 specific  immunity among adults in the community. The Health operations pillar of the WHE, unity desk of the WHO headquarters and the WHO Country Office for  Sri Lanka   jointly reviewed  the  proposal  for  the proposed survey. They also provided  technical  support to Sri Lanka to align  the seroprevalence survey proposal  with the Unity Studies: WHO sero-epidemiological investigations protocol.  

The proposed study is proven to be rational given the changed epidemiological situation of COVID-19 from intermittent cases to clusters and widespread transmission in the country   with  surges  due  to SARS CoV 2 variants, especially the Delta variant of concern  by July 2021.  In addition to the natural immunity, the population immunity was also rapidly being built up as a result of the roll-out of the COVID-19 vaccination programme  in the country. The COVID-19  immunization campaign was  started  from 28 January 2021. The campaign was launched with different types of COVID-19 vaccines.  

The study aims to determine the population level immunity against SARS-CoV-2 virus  through measuring seroprevalence of  SARS-CoV-2 specific  antibodies in adults. It is anticipated that findings of   the proposed study  will help the government take  relevant programme related decisions to implement  measures  to protect people against COVID-19.

Objectives of the seroprevalence study

  1. To measure seroprevalence of SARS-CoV-2 antibodies in the population of Sri Lanka by age and sex.
  2. To estimate the fraction of asymptomatic or subclinical infections in the population and by sex and age groups.
  3. To determine risk factors for infection by comparing the exposure of infected and non-infected individuals for COVID-19 infection in the study population.

The study design is a population based descriptive cross-sectional study. The study  will use  cluster sampling  technique. The clusters  to enroll the required sample size  will be selected  from nine districts. These districts   will be Colombo (including Colombo Municipal Council), Gampaha, Nuwara Eliya,  Galle, Kandy, Anuradhapura, Kalmunai, Jaffna and Kegalle. Health care staff for the study as study subjects will also be selected from the same districts.

The findings would help identify population immunity gaps for necessary interventions in terms of controlling transmission of SARS-CoV-2 in susceptible populations. The seroprevalence estimate would help the country   identify the true burden of infection in the community due to symptomatic and asymptomatic disease as well as the population immunity acquired due to COVID-19 vaccines.